Related Experiment Video
Updated: Jun 27, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Clinical characteristics, glycemic control & quality of life of patients using Android Artificial Pancreas System
Gabriella Lopes Ventura1, Laryssa da Silva Messias1, Maria Eduarda Pereira Dantas2
1Universidade Federal do Rio de Janeiro Rio de Janeiro RJ Brasil Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Objective:
This study evaluated the safety and efficacy of the Android Artificial Pancreas System (AAPS) in Brazilians with type 1 diabetes mellitus (T1D).
Subjects And Methods:
A total of 371 participants were surveyed, including 62 AAPS users and 309 non-users. AAPS configurations included continuous glucose monitoring (CGM ), Bluetooth transmitter (MiaoMiao), and a non-automated insulin pump.
Results:
AAPS users had a mean Time in Range (TIR) of 78.5% ± 16.6, with HbA1c levels decreasing from 7.3% ± 1.03 to 6.5% ± 0.7 (p < 0.001). Compared to non-AAPS users, AAPS users demonstrated better glycemic control, fewer severe hypoglycemic events (p = 0.006), and improved quality of life (p < 0.0001). However, 23.08% of AAPS users had a TIR below 70%, and time in level-2 hypoglycemia exceeded recommendations.
Conclusion:
These findings highlight AAPS as a low-cost alternative to commercial systems, with potential to expand access to automated therapy globally, particularly in resource-limited settings.
Related Concept Videos
Type I Diabetes I: Introduction
Type I Diabetes III: Clinical Manifestations
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Introduction
Type II Diabetes I: Introduction
Diabetes: Symptoms, Diagnosis, and Complications